HALOStock Financials & Fundamentals
Company Info
Company Full Name
Halozyme Therapeutics, Inc.
Full name of the company.
Industry Name
MEDICAL-BIOMED/GENETICS
Industry name
Major Industry Name
DRUGS
Major industry name
Sector Name
Medical
Sector name
Market Info
Current Price
$70.98
Current price of the stock
Trading Volume
$2M
Trading volume of the stock
Market Capitalization
$8.8B
Market capitalization of the company
Market Cap Category
Mid Cap
Category of market capitalization
Long-Term Growth Estimate
31.00%
Long-term growth mean estimate
Analyst Rating Mean
4.00
Mean analyst rating
Potential Upside
9.89%
Potential price appreciation based on analyst price targets
EPS Surprise Percentage Difference
-116.91%
Percentage difference of EPS surprise
Dividends
Dividend Change (1 Year)
-
Dividend change over 1 year
Dividend Rate
$0.00
Shows the amount of dividend paid
Balance Sheet
Total Debt to Equity Ratio
43.89
Total debt to total equity ratio
Current Ratio
4.66
Current ratio
Company Profitability
Gross Profit Margin
83.62%
Gross profit margin
Operating Profit Margin
33.58%
Operating profit margin
EBIT Margin
33.58%
Earnings before interest and taxes (EBIT) margin
EBITDA Margin
40.19%
Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin
Pretax Profit Margin
33.43%
Pretax profit margin
Net Profit Margin
22.69%
Net profit margin
Return on Equity (ROE)
649.18%
Measures profitability relative to shareholders' equity
Return on Tangible Equity
-20.94%
ROE excluding intangible assets
Return on Assets (ROA)
12.55%
Measures profitability relative to total assets
Return on Invested Capital (ROIC)
14.46%
Measures profitability relative to invested capital
Management Effectiveness
Asset Turnover (quarterly)
0.55
Asset turnover ratio
Inventory Turnover (quarterly)
1.30
Inventory turnover ratio
Receivables Turnover (quarterly)
3.17
Receivables turnover ratio
Days Sales Outstanding
115.33
Average number of days it takes to collect receivables
Valuation Measures
Price-to-Earnings (P/E) Ratio
27.73
Measures valuation relative to earnings
Forward P/E Ratio
9.15
P/E based on future earnings estimates
Price-to-Sales (P/S) Ratio
6.30
Measures valuation relative to sales
Price-to-Book (P/B) Ratio
171.28
Measures valuation relative to book value
Price-to-Operating Cash Flow (P/OCF) Ratio
5.89
Measures valuation relative to operating cash flow
Price-to-Free Cash Flow (P/FCF) Ratio
4.55
Measures valuation relative to free cash flow
Cash Flow Statement
Net Acquisitions/Divestitures
-1014
Indicates company's M&A activity
HALOStock Financials & Fundamentals
Company Info
| Parameter | Value | Description |
|---|---|---|
| Company Full Name | Halozyme Therapeutics, Inc. | Full name of the company. |
| Industry Name | MEDICAL-BIOMED/GENETICS | Industry name |
| Major Industry Name | DRUGS | Major industry name |
| Sector Name | Medical | Sector name |
Market Info
| Parameter | Value | Description |
|---|---|---|
| Current Price | $70.98 | Current price of the stock |
| Trading Volume | $2M | Trading volume of the stock |
| Market Capitalization | $8.8B | Market capitalization of the company |
| Market Cap Category | Mid Cap | Category of market capitalization |
| Long-Term Growth Estimate | 31.00% | Long-term growth mean estimate |
| Analyst Rating Mean | 4.00 | Mean analyst rating |
| Potential Upside | 9.89% | Potential price appreciation based on analyst price targets |
| EPS Surprise Percentage Difference | -116.91% | Percentage difference of EPS surprise |
Dividends
| Parameter | Value | Description |
|---|---|---|
| Dividend Change (1 Year) | - | Dividend change over 1 year |
| Dividend Rate | $0.00 | Shows the amount of dividend paid |
Balance Sheet
| Parameter | Value | Description |
|---|---|---|
| Total Debt to Equity Ratio | 43.89 | Total debt to total equity ratio |
| Current Ratio | 4.66 | Current ratio |
Company Profitability
| Parameter | Value | Description |
|---|---|---|
| Gross Profit Margin | 83.62% | Gross profit margin |
| Operating Profit Margin | 33.58% | Operating profit margin |
| EBIT Margin | 33.58% | Earnings before interest and taxes (EBIT) margin |
| EBITDA Margin | 40.19% | Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin |
| Pretax Profit Margin | 33.43% | Pretax profit margin |
| Net Profit Margin | 22.69% | Net profit margin |
| Return on Equity (ROE) | 649.18% | Measures profitability relative to shareholders' equity |
| Return on Tangible Equity | -20.94% | ROE excluding intangible assets |
| Return on Assets (ROA) | 12.55% | Measures profitability relative to total assets |
| Return on Invested Capital (ROIC) | 14.46% | Measures profitability relative to invested capital |
Management Effectiveness
| Parameter | Value | Description |
|---|---|---|
| Asset Turnover (quarterly) | 0.55 | Asset turnover ratio |
| Inventory Turnover (quarterly) | 1.30 | Inventory turnover ratio |
| Receivables Turnover (quarterly) | 3.17 | Receivables turnover ratio |
| Days Sales Outstanding | 115.33 | Average number of days it takes to collect receivables |
Valuation Measures
| Parameter | Value | Description |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | 27.73 | Measures valuation relative to earnings |
| Forward P/E Ratio | 9.15 | P/E based on future earnings estimates |
| Price-to-Sales (P/S) Ratio | 6.30 | Measures valuation relative to sales |
| Price-to-Book (P/B) Ratio | 171.28 | Measures valuation relative to book value |
| Price-to-Operating Cash Flow (P/OCF) Ratio | 5.89 | Measures valuation relative to operating cash flow |
| Price-to-Free Cash Flow (P/FCF) Ratio | 4.55 | Measures valuation relative to free cash flow |
Cash Flow Statement
| Parameter | Value | Description |
|---|---|---|
| Net Acquisitions/Divestitures | -1014 | Indicates company's M&A activity |